RVPH Valuation
Reviva Pharmaceuticals Holdings, Inc.
$
1.000
- Overview
- Forecast
- Valuation
RVPH Relative Valuation
RVPH's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RVPH is overvalued; if below, it's undervalued.
Historical Valuation
No Data
Competitors Valuation Multiple
The average P/S ratio for RVPH's competitors is 40.28, providing a benchmark for relative valuation. Reviva Pharmaceuticals Holdings, Inc. Corp (RVPH) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
People Also Watch
AVGO
Broadcom Inc
230.870
USD
-0.35%
MSFT
Microsoft Corp
453.720
USD
-0.97%
NVDA
NVIDIA Corp
132.840
USD
-1.15%
AMZN
Amazon.com Inc
201.500
USD
-1.26%
WMT
Walmart Inc
96.585
USD
-1.24%
TSLA
Tesla Inc
337.240
USD
-1.91%
META
Meta Platforms Inc
636.020
USD
-0.17%
XOM
Exxon Mobil Corp
104.360
USD
-0.56%
ORCL
Oracle Corp
157.870
USD
-1.52%
AAPL
Apple Inc
202.370
USD
-2.17%
FAQ
Is Reviva Pharmaceuticals Holdings, Inc. (RVPH) currently overvalued or undervalued?
Reviva Pharmaceuticals Holdings, Inc. (RVPH) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of 0.00. The fair price of Reviva Pharmaceuticals Holdings, Inc. (RVPH) is between to according to relative valuation methord.
What is Reviva Pharmaceuticals Holdings, Inc. (RVPH) fair value?
How does RVPH's valuation metrics compare to the industry average?
What is the current P/B ratio for Reviva Pharmaceuticals Holdings, Inc. (RVPH) as of May 21 2025?
What is the current FCF Yield for Reviva Pharmaceuticals Holdings, Inc. (RVPH) as of May 21 2025?
What is the current Forward P/E ratio for Reviva Pharmaceuticals Holdings, Inc. (RVPH) as of May 21 2025?